Trials / Completed
CompletedNCT03927209
A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.
A Phase I, Open-label, Positron Emission Tomography Study in Healthy Male Subjects to Explore the Inhibition of Monoamine Oxidase B in the Brain After Multiple Oral Doses of BI 1467335 (Non-randomized, Open-label, Parallel-group Study)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 21 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this trial is to investigate the effect of multiple oral dosing of high dose BI 1467335 over 28 days and multiple oral dosing of low dose BI 1467335 over 42 days on MAO-B occupancy in the brain compared to baseline using \[11C\]-L-deprenyl-D2 PET tracer in healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1467335 | tablet |
Timeline
- Start date
- 2019-06-06
- Primary completion
- 2019-11-22
- Completion
- 2019-11-22
- First posted
- 2019-04-25
- Last updated
- 2021-06-22
- Results posted
- 2021-06-04
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03927209. Inclusion in this directory is not an endorsement.